Key Financial Highlights:
Q4 FY25:
· Revenue from operations at Rs. 65,279 mn, up 18% over last year.
· Research & Development (R&D) investments for the quarter stood at Rs. 4,799 mn (7.4% of revenues).
· EBITDA for the quarter was Rs. 21,255 mn, up 30% YoY. EBITDA margin for the quarter stood at 32.6%, which is an improvement of 310 bps on a YoY basis.
· Net Profit, adjusted for exceptional items, was Rs. 13,905 mn, up 18% YoY.
· Capex (organic) for the quarter was Rs. 3,202 mn.
Full Year FY25:
· Revenue from operations at Rs. 2,32,415 mn, up 19% over last year.
· Research & Development (R&D) investments for the year stood at Rs. 18,555 mn (8.0% of revenues).
· EBITDA for the year was Rs. 70,585 mn, up 31% YoY. EBITDA margin for the year stood at 30.4%, which is an improvement of 290 bps over the previous year.
· Net Profit, adjusted for exceptional items, was Rs. 47,451 mn, up 23% YoY.
· Capex (organic) for the full year was Rs. 12,140 mn.
· Net Debt to Equity ratio as on 31st March, 2025 was -0.20x while Net Debt to EBITDA stood at -0.69x at the end of March, 2025. Net Cash (negative Net Debt) as on March 31st, 2025 was Rs. 48,836 mn.
Operational & Strategic Updates:
US formulations business registered robust 24% YoY growth in Q4, now accounting for 50% of consolidated revenues.
The Consumer Wellness segment delivered double-digit growth, underpinned by innovation and portfolio expansion.
Key manufacturing sites successfully completed USFDA inspections without observations, reinforcing Zydus’ commitment to global quality standards.
Continued momentum in the innovation pipeline with USFDA approvals for pivotal clinical trials and new vaccine development.
Please find below the quote from Dr. Dr. Sharvil Patel, Managing Director – Zydus Lifesciences Limited
“We are happy to conclude FY 2025 on a strong note, with all our businesses surpassing our growth expectations. The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth. We look forward to continued execution success and deepening strategic partnerships to drive long term growth. Our commitment to maintaining the highest quality standards across our operations remains unwavering.” – Dr. Sharvil Patel, Managing Director – Zydus Lifesciences Limited.